Simon N. Haydar

459 total citations
17 papers, 341 citations indexed

About

Simon N. Haydar is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Simon N. Haydar has authored 17 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Pharmacology and 7 papers in Organic Chemistry. Recurrent topics in Simon N. Haydar's work include Receptor Mechanisms and Signaling (8 papers), Nicotinic Acetylcholine Receptors Study (7 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). Simon N. Haydar is often cited by papers focused on Receptor Mechanisms and Signaling (8 papers), Nicotinic Acetylcholine Receptors Study (7 papers) and Cholinesterase and Neurodegenerative Diseases (6 papers). Simon N. Haydar collaborates with scholars based in United States and Italy. Simon N. Haydar's co-authors include John Dunlop, Thomas A. Comery, Chiara Ghiron, Carla Scali, Renza Roncarati, Hendrick Bothmann, Riccardo Zanaletti, A. Paul Krapcho, Cody Kelley and Georg C. Terstappen and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Hepatology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Simon N. Haydar

17 papers receiving 329 citations

Peers

Countries citing papers authored by Simon N. Haydar

Since Specialization

Citations

This map shows the geographic impact of Simon N. Haydar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon N. Haydar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon N. Haydar more than expected).

Fields of papers citing papers by Simon N. Haydar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon N. Haydar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon N. Haydar. The network helps show where Simon N. Haydar may publish in the future.

Co-authorship network of co-authors of Simon N. Haydar

This figure shows the co-authorship network connecting the top 25 collaborators of Simon N. Haydar. A scholar is included among the top collaborators of Simon N. Haydar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon N. Haydar. Simon N. Haydar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	PS-073-Preclinical profile of HBV core protein inhibitor, ABI-H, a potent inhibitor of cccDNA generation in HBV infected cells 2019 ·Journal of Hepatology ·Qi Huang, Simon N. Haydar, Yi Zhou, Dawei Cai, Xiang Xu, Ran Yan, (unknown), (unknown), (unknown), Michael S. Walker, Roopa Rai, Mark G. Bures, Leping Li, (unknown)	4
2	Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor 2014 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Thomas A. Comery, John Dunlop, (unknown), Chiara Ghiron, Simon N. Haydar, Laura Maccari, (unknown), Elisa Turlizzi, Riccardo Zanaletti, Jean Zhang	16
3	N-[5-(5-Fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A Medicinal Chemistry Effort toward an α7 Nicotinic Acetylcholine Receptor Agonist Preclinical Candidate 2012 ·Journal of Medicinal Chemistry ·Riccardo Zanaletti, Laura Bettinetti, (unknown), Ilaria Ceccarelli, (unknown), Thomas A. Comery, John Dunlop, (unknown), Chiara Ghiron, Simon N. Haydar, Flora Jow, Laura Maccari, (unknown), (unknown), Carmela Pratelli, Carla Scali, Elisa Turlizzi, Michela Valacchi	12
4	Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789) 2012 ·Journal of Medicinal Chemistry ·Riccardo Zanaletti, Laura Bettinetti, (unknown), (unknown), Thomas A. Comery, John Dunlop, G. Gaviraghi, Chiara Ghiron, Simon N. Haydar, Flora Jow, Laura Maccari, (unknown), (unknown), Carla Scali, Elisa Turlizzi, Michela Valacchi	21
5	Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625 2011 ·Psychopharmacology ·Karen L. Marquis, Thomas A. Comery, Flora Jow, Rachel L. Navarra, Steven M. Grauer, Claudine Pulicicchio, Cody Kelley, Julie Brennan, Renza Roncarati, Carla Scali, Simon N. Haydar, Chiara Ghiron, Georg C. Terstappen, John Dunlop	15
6	Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease 2010 ·Current Topics in Medicinal Chemistry ·Simon N. Haydar, John Dunlop	80
7	P3‐329: SAM‐531, N,N‐dimethyl‐3‐{[3‐(1‐naphthylsulfonyl)‐1H‐indazol‐5‐yl]oxy} propan‐1‐amine, a novel serotonin‐6 receptor antagonist with preclinical pro‐cognitive efficacy 2010 ·Alzheimer s & Dementia ·Thomas A. Comery, Suzan Aschmies, Simon N. Haydar, Zoë A. Hughes, Christine Huselton, Dianne Kowal, Angela Krämer, (unknown), Michael M. Monaghan, Deborah L. Smith, Guo‐Ming Zhang, Jean Zhang, Meiyi Zhang, Peter H. Reinhart, (unknown), Menelas N. Pangalos	6
8	5-Cyclic Amine-3-arylsulfonylindazoles as Novel 5-HT₆ Receptor Antagonists 2010 ·Journal of Medicinal Chemistry ·Simon N. Haydar, (unknown), (unknown), James F. Mattes, Jean Zhang, Angela Krämer, Deborah L. Smith, Christine Huselton, Radka Graf, Suzan Aschmies, Lee E. Schechter, Thomas A. Comery, Albert J. Robichaud	14
9	Synthesis of Novel 4-Fluoro-2H-pyrazol-3-ylamines 2010 ·Synthetic Communications ·(unknown), Chiara Ghiron, Simon N. Haydar, (unknown), Riccardo Zanaletti	4
10	1-(2-Aminoethyl)-3-(arylsulfonyl)-1H-pyrrolopyridines are 5-HT6 receptor ligands 2009 ·Bioorganic & Medicinal Chemistry Letters ·Ronald C. Bernotas, Schuyler Antane, (unknown), Simon N. Haydar, Albert J. Robichaud, Boyd L. Harrison, (unknown), Deborah L. Smith, Joseph Coupet, Lee E. Schechter	8
11	SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist 2009 ·Bioorganic & Medicinal Chemistry ·Simon N. Haydar, Chiara Ghiron, Laura Bettinetti, Hendrick Bothmann, Thomas A. Comery, John Dunlop, Salvatore La Rosa, (unknown), (unknown), (unknown), Renza Roncarati, Carla Scali, Michela Valacchi, M. Varrone, Riccardo Zanaletti	36
12	Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Renza Roncarati, Carla Scali, Thomas A. Comery, Steven M. Grauer, (unknown), Hendrick Bothmann, Brian Jow, Dianne Kowal, Marco Gianfriddo, Cody Kelley, Ugo Zanelli, Chiara Ghiron, Simon N. Haydar, John Dunlop, Georg C. Terstappen	88
13	Heterobiaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases. Part II 2009 ·Bioorganic & Medicinal Chemistry Letters ·Michael P. Trova, Keith D. Barnes, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Simon N. Haydar, R. Jason Herr, Hui Yu, Matthew R. Johnson, John M. Lehman, (unknown), Matthew P. Rainka, (unknown), (unknown), Steven W. Tregay, Xiaozhang Zheng, Thomas Friedrich	14
14	Novel Oxidation of Cyclosporin A: Preparation of Cyclosporin Methyl Vinyl Ketone (Cs-MVK) 2009 ·Synlett ·Bruce F. Molino, Zhicai Yang, (unknown), Simon N. Haydar, (unknown), Frédéric Y. Bois, Jun‐Ho Maeng, (unknown), Joseph O. Rich, Yuri L. Khmelnitsky, Thomas Friedrich, (unknown), Peter C. Michels	3
15	Synthesis of regioisomeric 2,5‐bis‐substituted‐aza‐benzothiopyranoindazoles 2001 ·Journal of Heterocyclic Chemistry ·A. Paul Krapcho, Simon N. Haydar	4
16	Synthesis and antitumor activities of 5-methyl-1- and 2-[[2-dimethylaminoethyl]amino]-aza-thiopyranoindazoles 2000 ·Bioorganic & Medicinal Chemistry Letters ·A. Paul Krapcho, Simon N. Haydar, (unknown), Miles P. Hacker, E. MENTA, Gino Beggiolin	9
17	N,N,5‐trimethyl‐1H‐benzothiopyrano[4,3,2‐cd]‐indazole‐1‐ethanamine — A novel heterocycle 1997 ·Journal of Heterocyclic Chemistry ·A. Paul Krapcho, Simon N. Haydar	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact